EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use

Katherine Colvin

EMJ Oncology · 2022

DOI: 10.33590/emjoncol/10128767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMJ Oncology, 2022. Verfasst von Katherine Colvin.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EXPLORING the current state of use of immunotherapies in the treatment of non-small cell lung cancer (NSCLC) and looking to future immunotherapeutic pathways, three expert speakers presented a session at European Society for Medical Oncology (ESMO) Congress 2022, on the 12 th of September.The speakers shared insights on personalising current uses of immunotherapeutics in NSCLC, the use of immunotherapies in patient populations traditionally excluded from clinical trials, and the immune pathways and strategies that could be utilised in future immunotherapeutic management of lung cancer.

Zitieren

APA

Colvin, K. (2022). Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use. EMJ Oncology. https://doi.org/10.33590/emjoncol/10128767

Vancouver

Colvin K. Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use. EMJ Oncology. 2022. doi:10.33590/emjoncol/10128767

BibTeX
@article{Colvin2022,
  author = {Colvin, Katherine},
  title = {Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use},
  journal = {EMJ Oncology},
  year = {2022},
  doi = {10.33590/emjoncol/10128767}
}
Kostenlos starten →